{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-017868","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.888052+00:00","generated_at":"2026-06-23T19:34:15.067687+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Beam announces FDA formal clinical hold letter for BEAM-201 IND; plans Q4 2022 response","bullets":["FDA placed BEAM-201 IND on clinical hold for relapsed/refractory T-ALL/T-LBL.","Letter dated Aug 25 requests additional control data and off-target editing analyses.","Requests also include additional cytokine assay data and updated investigator brochure.","Beam intends to complete studies and submit Complete Response in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-017868","json":"https://secwatch.observer/filing/0000950170-22-017868.json","markdown":"https://secwatch.observer/filing/0000950170-22-017868.md","text":"https://secwatch.observer/filing/0000950170-22-017868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022017868/0000950170-22-017868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022017868/beam-20220825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T19:34:15.067687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}